Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Jun 29, 2020

BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO

Andrea L. Acosta to be Promoted to Group Vice President, Chief Accounting Officer

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President,...
Jun 23, 2020

BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate...
Jun 17, 2020
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit

96% Mean Reduction in Factor VIII Usage

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an...
- Photos 3
Jun 3, 2020

BioMarin to Participate in Two Upcoming Virtual Investor Conferences

- Jefferies Virtual Healthcare Conference on June 4

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and...
May 31, 2020

BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

All Study Participants Remain off Prophylactic Therapy

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...